ÂÜÀòÂÒÂ×

Mélanie Wilbaux's work experience begins with their current position as a Senior Scientist at Pumas-AI, Inc. since 2023. Prior to this, they worked at Novartis from 2017 to 2023, where they held the roles of Senior Principal Pharmacometrics Scientist and Principal Pharmacometrics Scientist. In these positions, Mélanie led the planning, execution, and delivery of pharmacometrics strategy in clinical drug development for oncology and immunology projects, provided support for regulatory submissions, and contributed to drug development decisions.

Before joining Novartis, Mélanie worked at the University Children's Hospital Basel from 2014 to 2017. Mélanie'srole there was focused on characterizing and forecasting weight changes in term neonates and identifying potential complications arising from excessive weight loss in newborns.

Prior to their time at the University Children's Hospital Basel, Mélanie worked at EMR 3738 CTO (therapeutiC Targeting in Onclogy) from 2011 to 2014. During this period, they completed their PhD in Pharmacometrics, where they developed mathematical models to describe treatment effects on tumor growth and biomarker kinetics, and predict treatment efficacy. Additionally, Mélanie worked on a master's thesis, focusing on mathematical modeling of tumor size and CA-125 kinetics in relapsed ovarian cancer patients.

In 2010, Mélanie also worked at EMR 3738 CTO (therapeutiC Targeting in Onclogy) as part of a master's thesis project. Mélanie'swork involved a toxicogenomic study of the effects of exposure to 1-3 dinitrobenzene on male reproductive health and endocrine toxicity in adult rats. Mélanie developed a method to study toxicity and characterize the Benchmark Dose for a variety of genes resulting from DNA chips.

Mélanie Wilbaux's education history starts in 2005 when they obtained their Baccalauréat Général Scientifique from Lycée Louis Aragon in Givors, France. In the same year, they also enrolled at the University Claude Bernard Lyon 1, where they earned their Bachelor's Degree in Biology in 2009. Following their undergraduate studies, Mélanie pursued further education at the University Claude Bernard Lyon 1, completing a Master's degree in Biostatistics, Modeling, Pharmacology, and Clinical Trials from 2009 to 2011. Mélanie's academic journey continued with a University Degree in Industrial Management Systems, which they obtained in 2013. Lastly, Mélanie Wilbaux completed their highest level of education, a Ph.D. in Pharmacometrics, from the University Claude Bernard Lyon 1 between 2011 and 2014.